The biologics manufacturing sector is in the middle of the largest sustained growth cycle of any pharmaceutical category. The numbers are unambiguous. The global biologics manufacturing market is projected to grow from $40.1 billion in 2025 to $192.5 billion by 2035, a 17% compound annual growth rate, according to FactMR’s December 2025 industry forecast. The biologics outsourcing market alone is projected to grow from $22.58 billion in 2025 to $42.43 billion by 2030 at a 13.5% CAGR, per Research and Markets analysis published April 2026.
The capital is moving. The capacity is being built. The pipelines are full. North America holds 36% of global biologics contract manufacturing share, with the U.S. leading global biologics revenue.
What is not keeping up is the HR infrastructure required to actually staff, retain, and develop the workforce that the growth cycle demands.
This is not a small problem. It is the single largest constraint on the U.S. biologics sector’s ability to convert announced capacity into validated production over the next decade.
Global Location Strategies, in its 2026 Best Places for Pharmaceutical Manufacturing Insights Report, identified the constraint directly. Of 387 U.S. metropolitan areas evaluated against the labor requirements for large-scale biologics manufacturing, only 33 had the minimum labor base of 1,750 biopharma workers required to support a new facility. The biologics industry’s relatively small size, the report noted, limits workforce availability. Only a few regions can supply enough talent to support the major expansions being announced.
The BioPlan Associates 2025 industry survey, cited in the Cytiva Global Biopharma Index, put the trend in context. Over the past 15 years, more than 50% of the bioprocessing industry has experienced significant hiring difficulties. Demand for skilled staff has consistently exceeded the output of training programs and university pipelines, even in regions with strong academic infrastructure.
IntuitionLabs’ October 2025 analysis confirmed the pattern at the company level. Essentially all major biopharma companies, the report noted, cite difficulties finding experienced biomanufacturing personnel when they expand facilities. The skill set is niche, requiring understanding of both biology and industrial operations under Good Manufacturing Practices, and the supply pipeline through universities and community colleges has not kept pace with demand.
The workforce constraint becomes more acute when overlaid with the geographic distribution of biologics expansion.
Major biologics manufacturing investments in 2025 and 2026 have been announced or expanded in North Carolina, New Jersey, Pennsylvania, Ohio, South Carolina, and Massachusetts simultaneously, according to Pharma Search Partners’ 2026 industry analysis. These plants will need validation engineers, QC scientists, QA leadership, automation specialists, and manufacturing operators, all roles that have historically been difficult to scale quickly.
The geographic implication is significant. Most biologics HR functions were built to support growth in one or two campus environments, typically in established hubs like Boston, Research Triangle, San Diego, or the New Jersey-Pennsylvania corridor. The current environment requires hyperscaling across six or more regional sites simultaneously, with each site competing for talent in its own local market against both biologics competitors and other manufacturing sectors.
A centralized HR function designed to support 1,000 employees across two locations cannot effectively scale to support 5,000 employees across six locations without structural redesign. Most biologics organizations are attempting that scaling without the redesign, and the result is predictable.
Four HR infrastructure failures consistently show up in biologics organizations attempting to scale during the current cycle.
Time-to-hire is stretching. Specialized biologics roles routinely take 90 to 120 days to fill, with senior roles running 150+ days. Recruiting cycles built around 60-day fill targets are no longer realistic. The HR teams attempting to maintain historical fill targets are doing so by lowering candidate quality bars, which produces the second failure.
Year-one turnover is rising. Pharmaceutical Technology’s annual workforce survey, conducted in Q4 2025 and published in early 2026, documented that voluntary turnover among bio/pharma professionals rose from 13.71% in 2024 to 15.91% in 2025. Compressed hiring timelines lead to weaker fits, weaker fits lead to higher first-year departures, and the cycle reinforces itself.
Retention investment is reactive. In the biologics talent market, every senior person is a known quantity to specialized recruiters. By the time an HR team learns that a critical employee is considering an offer from a competitor, the retention conversation is already too late. The companies that win biologics retention are the ones managing it proactively, not reactively.
Specialty hiring is being run with generalist tools. Validation engineers, QC scientists, automation specialists, and bioprocess engineers each require different sourcing strategies, different compensation benchmarking, and different retention models. HR teams running all of these through a single generalist talent acquisition function are systematically losing on each.
The HR challenge in biologics manufacturing is amplified by the dominant role of CDMOs in the sector. According to Global Growth Insights’ April 2026 analysis, 61% of major sponsors prefer strategic outsourcing partnerships for flexible biologics capacity, and 63% of larger sponsors maintain external production partnerships.
This means biologics talent is not just being hired by sponsors. It is being hired by CDMOs, sponsors, hybrid models, and increasingly by the biologics manufacturing operations of major pharma companies that are building or expanding internal capacity. The Cytiva 2025 index found that 57% of firms had increased their use of CDMOs in the past year. Each of those CDMOs is hiring against the same talent pool sponsors are hiring against.
The HR functions on both sides of this equation are competing for the same finite supply.
The biologics organizations that are actually scaling their HR infrastructure to match the growth cycle are doing four things differently than their peers.
They are building geographic depth. Embedded site HR leadership with local market expertise, local talent partner networks, and direct accountability to regional operations leadership is replacing the centralized HR-business-partner model. Centralized HR cannot be present in six regional markets simultaneously.
They are specializing the talent acquisition function. Generic biotech recruiters cannot effectively compete for validation engineers and bioprocess specialists at scale. Sophisticated organizations have built specialty recruiting capability, often through partnerships with executive search and staffing firms that have deep regional talent pipelines for specific role categories.
They are managing retention proactively. Compensation benchmarking is being refreshed quarterly rather than annually for critical biologics roles. High-value retention conversations are happening before someone gets an offer, not after. Stay interviews are replacing exit interviews as the primary diagnostic tool.
They are treating HR infrastructure as part of capital planning. When a biologics expansion is approved, the HR infrastructure investment is being scoped, budgeted, and approved alongside the facility investment. HR is being treated as enabling infrastructure for growth, not as a downstream administrative function that will somehow scale along with the building.
The biologics growth cycle is going to compound for at least another decade. Companies that build the HR infrastructure to support it will translate the growth into competitive position. Companies that do not will hit a ceiling that capital cannot break through.
Three questions belong on the next biologics board agenda.
First, has the HR function been formally redesigned for the current growth rate, or is it still operating on the structure that supported the previous, slower growth cycle? If the structure has not been redesigned, it is currently the rate-limiter on growth.
Second, are HR investment decisions being scoped alongside capital investment decisions, or are they being made downstream after facility decisions are locked? The latter approach guarantees an HR capability gap when facilities come online.
Third, are specialty talent partnerships being treated as strategic infrastructure or as vendor relationships? In a structurally tight talent market, the partners who can compete for the right candidates are not interchangeable with the partners who fill general requisitions.
The biologics sector is going to grow whether the HR infrastructure scales with it or not. The companies that scale their HR infrastructure will own the next decade of biologics manufacturing leadership. The companies that do not will spend the next decade explaining why their announced capacity never reached its announced production targets.
RX2 Solutions is a workforce solutions firm specializing in HR outsourcing, executive search, and strategic staffing. We partner with organizations to build high-performing teams through customized talent strategies, leadership placement, and scalable workforce solutions.
📞 Phone: 610.340.3490
📧 Email: info@rx2solutions.com
🌐 Website: www.rx2solutions.com
RX2 Solutions
A Respectfully Professional People Company